Kerr on Oncology

 
 

  • Predicting Colon Cancer Relapse: Test Gets an 'A'   Dr David Kerr reviews new research on a molecular test that can help determine which patients should receive adjuvant chemotherapy for early-stage colon cancer.
  • Counting Colorectal Tumors During Flights to Asia   After much retrospection and many transpacific airline flights, Dr Venook shares with Dr Kerr his research on sidedness of CRC and its effect on management of four apparent disease subtypes.
  • Cetuximab Continuation After CRC Progression May Up PFS   Dr David Kerr reports on a phase 2 study suggesting that continuation of cetuximab after progression may improve progression-free survival in patients with metastatic colorectal cancer.
  • Diabetes in CRC Survivors: How Big Is the Risk?   Diabetes increases risk for colorectal cancer. But does colorectal cancer increase risk for diabetes? Dr David Kerr reviews a population-based study that may serve as a caution for cancer survivors.
  • The Two-Sided Issue of Colorectal Cancer   Dr David Kerr previews key colorectal cancer abstracts from ASCO 2016 that range from combinations of checkpoint inhibitors to the prognostic value of tumor location.
  • Is Colorectal Cancer on the Run?   The US incidence of CRC has declined by 40% since 1975. Contributory factors include screening, better treatment, and possibly use of aspirin and changes in gut microbiome reports Dr David Kerr.
  • New Wrinkle in Cancer Growth Precept   Dr David Kerr explains a new theory as to how cancer may gain blood supply by a process other than angiogenesis, which may provide insight into mechanisms of resistance to antiangiogenic agents.
  • Metformin Active in Reducing Colorectal Polyp Recurrence   Dr David Kerr reports on a randomized study in which low-dose metformin reduced recurrence of colorectal polyps from 56% to 38%. Is metformin potentially another strategy to prevent colorectal cancer?
  • Genetic Test May Identify CRC Risk in 'Normals'   A study describes a genetic 'signature' able to identify normal individuals at higher and lower risk of developing colorectal cancer--which has strong implications for screening, says Dr David Kerr.
  • Survival Benefit of SIRT in mCRC Uncertain   Dr David Kerr looks at a study of selective internal radiation therapy in hepatic metastatic colorectal cancer, but says the lack of survival data puts the clinical utility of SIRT in question.
  • New Biomarker for Yea or Nay to Chemo in Early CRC   Dr David Kerr gives the thumbs-up to new data on CDX2, a prognostic biomarker whose absence identifies colorectal cancer patients likely to benefit from adjuvant chemo, but says validation is needed.
  • Too Much Surveillance in Early CRC: Not a Good Thing   Intensive surveillance after resection of early-stage colorectal cancer does not improve survival and adds cost without adding value, says Dr David Kerr, reporting on the findings of a recent study.
  • Multidisciplinary Cancer Teams Alive and Well Globally   Dr David Kerr discusses a survey of ASCO members practicing outside of the United States about their involvement in multidisciplinary team cancer care, and discovers that teamwork is flourishing.
  • Say No to Intensified Chemo in the Elderly   A study in patients with advanced colorectal cancer (median age, 80) found that adding irinotecan to 5-FU/leucovorin provided no benefit, prompting Dr David Kerr to assess chemo in the truly elderly.
  • Pharmacogenetic Testing for 5-FU Saves Lives and Money   Prospective screening for a genetic variant of DPD, an enzyme that catabolizes 5-FU, reduces mortality from 10% to 0% in patients with this variant and is cost-effective. Dr David Kerr is all for it.
  • Metronomic Capecitabine as mCRC Maintenance Therapy   Dr David Kerr discusses a small study that provides provocative results for using metronomic, low-dose, oral capecitabine as single-agent maintenance therapy in advanced colorectal cancer.
  • Is Capecitabine New Standard in Pre-op Rectal Cancer?   Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice.
  • Can Coffee KO Cancer's Return?   Early data suggest that coffee intake may reduce the recurrence rate of colon cancer, prompting Dr David Kerr to question whether to recommend that CRC patients have another cup (or two) of joe.
  • Oral Adjuvant CRC Therapy: How Little Is Enough?   Dr David Kerr comments on a study reporting that 6 months of oral UFT/LV for stage IIB/III colon cancer therapy is as effective as 18 months of treatment. He asks: Can we shorten treatment further?
  • Oncologists as a Force for Cancer Prevention?   Dr David Kerr suggests that oncologists combine patient care with public medicine and become a frontline force in advocating for public health and cancer prevention.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.